Improving the safety of gene therapies 2 different ways
Two groups of researchers have developed unique approaches to overcome the limitations of delivery of gene editing therapeutics. In a pair of new papers, researchers describe methods for more efficient and safe delivery of CRISPR components to targeted cells and tissues.  Discuss
UCB expands gene therapy capabilities
UCB has acquired Belgium-based Handl Therapeutics and formed a new collaboration with Florida-based Lacerta Therapeutics to accelerate the company's gene therapy activities.
Proteintech, HebeCell to develop cancer immunotherapies
Proteintech and HebeCell have announced a partnership to develop nanobody-based chimeric antigen receptors for cancer cellular immunotherapy use.
WuXi increases GMP plasmid DNA services
WuXi Advanced Therapies has expanded its cell and gene therapy platforms with capabilities to provide high-quality and cost-effective good manufacturing practice (GMP) plasmids.
Pluristyx supports Kiadis' COVID-19 NK cell therapy
Pluristyx will be supporting Kiadis Pharma and the Advanced Regenerative Manufacturing Institute's BioFabUSA program by providing services for the research and development of Kiadis' natural killer (NK) cell COVID-19 therapy.
Digital microfluidic technique connects cells to their environment
A new digital microfluidic technique allows researchers to connect physical cell properties with the molecular makeup of individual cells. This new approach, published in Nature Communications on November 11, will enable a deeper study of stem cells and other rare cell types for therapeutic development.  Discuss
AGTC touts positive early clinical results for gene therapy
Applied Genetic Technologies (AGTC) has reported positive data from its ongoing phase I/II clinical trial evaluating its adeno-associated virus (AAV)-based gene therapies in patients with X-linked retinitis pigmentosa.
Intellia to advance CRISPR treatment for sickle cell
Intellia Therapeutics has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease treatments using its CRISPR/Cas9 genome editing technology.
Factor Bioscience receives 2nd patent for mRNA vector tech
Factor Bioscience has received its second U.S. patent in 2020 for its messenger RNA (mRNA) vectorization technology of transcription activator-like effector nucleases.
Locus Biosciences to develop K. pneumoniae-targeting phage therapy
Locus Biosciences will develop its LBP-KP01, CRISPR-Cas3-enhanced bacteriophage product targeting Klebsiella pneumoniae with a $12.5 million partnership with the global nonprofit Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter